Literature DB >> 11727528

Alphavirus vectors: development and potential therapeutic applications.

S Schlesinger1.   

Abstract

Alphaviruses are RNA enveloped viruses that are proving their value as expression vectors. They are particularly well-suited for this role as they are easily and quickly engineered and can be used to produce high levels of proteins of interest. A promising and important use is as vaccines against disease-causing agents such as HIV. The three alphaviruses now serving as vectors are Sindbis virus, Semliki Forest virus (SFV) and Venezuelan equine encephalitis (VEE) virus. Sindbis virus and SFV are well-known models for studies in molecular and cell biology; VEE virus is a human pathogen and had received some previous notoriety as a potential biological weapon. It is now becoming a potentially valuable vaccine vector. All three viruses are being tested as vaccines but, at present, only Sindbis virus and SFV have been considered for other uses. Sindbis virus vectors have been developed to screen libraries for the identification of new proteins and to devise sensitive assays to detect viruses more difficult to grow in culture. Both Sindbis virus and SFV vectors are serving as tools for fundamental studies in biology, examples include development in insects and analysis of protein functions in neuronal cells. In this article the replication strategy of alphaviruses and the different ways they can be engineered to serve as expression vectors is described. This provides an introduction to the ways these vectors have been used and illustrates the promise these vectors offer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11727528     DOI: 10.1517/14712598.1.2.177

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  32 in total

1.  Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Leroy N Hwang; Elke S Bergmann-Leitner; Steven E Finkelstein; Stephan Frank; Nicholas P Restifo
Journal:  Vaccine       Date:  2004-03-29       Impact factor: 3.641

Review 2.  Viral vector-based therapeutic cancer vaccines.

Authors:  Cecilia Larocca; Jeffrey Schlom
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

3.  Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.

Authors:  Soumi Gupta; Ramesh Janani; Qian Bin; Paul Luciw; Catherine Greer; Silvia Perri; Harold Legg; John Donnelly; Susan Barnett; Derek O'Hagan; John M Polo; Michael Vajdy
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 4.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

5.  Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Authors:  Elizabeth A Reap; Sergey A Dryga; John Morris; Bryan Rivers; Pamela K Norberg; Robert A Olmsted; Jeffrey D Chulay
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

6.  Rubella virus-like replicon particles: analysis of encapsidation determinants and non-structural roles of capsid protein in early post-entry replication.

Authors:  Claudia Claus; Wen-Pin Tzeng; U G Liebert; Teryl K Frey
Journal:  J Gen Virol       Date:  2011-11-23       Impact factor: 3.891

7.  Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins.

Authors:  Gillis R Otten; Mary Schaefer; Barbara Doe; Hong Liu; Indresh Srivastava; Jan zur Megede; Jina Kazzaz; Ying Lian; Manmohan Singh; Mildred Ugozzoli; David Montefiori; Mark Lewis; David A Driver; Thomas Dubensky; John M Polo; John Donnelly; Derek T O'Hagan; Susan Barnett; Jeffrey B Ulmer
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.

Authors:  Silvia Perri; Catherine E Greer; Kent Thudium; Barbara Doe; Harold Legg; Hong Liu; Raul E Romero; Zequn Tang; Qian Bin; Thomas W Dubensky; Michael Vajdy; Gillis R Otten; John M Polo
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Double subgenomic alphaviruses expressing multiple fluorescent proteins using a Rhopalosiphum padi virus internal ribosome entry site element.

Authors:  Michael R Wiley; Lisa O Roberts; Zach N Adelman; Kevin M Myles
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

10.  Processing of a pestivirus protein by a cellular protease specific for light chain 3 of microtubule-associated proteins.

Authors:  Jens Fricke; Christiane Voss; Michael Thumm; Gregor Meyers
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.